BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...play BioShin Ltd. as COO in 2018 and is now CEO. BioShin, a Shanghai-based subsidiary of Biohaven Pharmaceutical Holding Co. Ltd....
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...Lyfe Capital, Maven Investment Partners US, Lilly Asia Ventures and Eight Roads Ventures.Migraine milestone for Biohaven Enrollment...
...Phase II/III trial of oral migraine product zavegepant triggered a $100 million milestone payment to Biohaven Pharmaceutical Holding Co. Ltd....
...NYSE:BHVN) from Royalty Pharma plc (NASDAQ:RPRX).TARGETSPGE2 – Prostaglandin E2PPARα – Peroxisome proliferation activated receptorα BC Staff Zavegepant (BHV-3500) Qihan Biotechnology Inc. Biohaven Pharmaceutical Holding Co. Ltd. Royalty...
BioCentury | Mar 3, 2021
Finance

March 3 Venture Roundup: Bionaut debuts with $20M; plus Janux, Century, Caribou, Medilink, Oxular and more

...in a series A-2 round led by existing investor Hatteras Venture Partners and new investor Biohaven...
...also participating were CT Innovations, Elm Street Ventures and Osage University Partners. Artizan also granted Biohaven...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...commercialization rights to verdiperstat in ALS to Biohaven Pharmaceutical Holding Co. Ltd....
BioCentury | Jan 20, 2021
Product Development

Alzheimer’s marks fourth late-stage miss for Biohaven’s glutamate modulator

...By selina koch, executive editor Biohaven’s glutamate modulator troriluzole has missed its primary endpoint in a...
...neurological indication, this time Alzheimer’s disease. That won’t necessarily prevent the company from advancing the therapy.Biohaven Pharmaceutical Holding Co. Ltd....
...is a third-generation prodrug of riluzole, a generic with modest efficacy in amyotrophic lateral sclerosis. Biohaven...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...other autoimmune diseases. The deal terms include $75 million in upfront Zai equity and $100 million in milestones and other payments.Biohaven...
...Kleo Pharmaceuticals Inc., acquiring two immune modulating platforms. The merger values Kleo at about $20 million. Biohaven...
...also entered a license agreement with Yale University for an extracellular target degrader platform. The company established Biohaven...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...Tuesday.Biohaven, Sosei Heptares in CGRP dealThe Sosei Heptares unit of Sosei Group Corp. (Tokyo:4565) granted Biohaven Pharmaceutical Holding Co. Ltd....
...up front plus research funding, and is eligible for $370 million in milestones, plus royalties. Biohaven...
...if that sale would cause or worsen a drug shortage. TARGETSCGRP – Calcitonin gene-related peptide BC Staff Biohaven Pharmaceutical Holding Co. Ltd. Sosei...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

...Brukinsa, the second-biggest increase was for migraine therapy Nurtec rimegepant, an oral disintegrating tablet from Biohaven Pharmaceutical Holding Co. Ltd....
...during the pandemic (see “Sizing Up Commercial Launches During Pandemic”). In its 2Q quarterly earnings report, Biohaven...
...ODT, rimegepant (BHV-3000, bms-927711) Ubrelvy, ubrogepant (MK-1602) Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) BeiGene Ltd. Sage Therapeutics Inc. Novartis AG Amgen Inc. Biohaven Pharmaceutical Holding Co. Ltd. AbbVie...
BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

...Mass., beginning April 1 at the latest; he is president of nutrition and biosciences at DuPont.Biohaven Pharmaceutical Holding Co. Ltd....
...was president and GM China of Bristol Myers Squibb Co. (NYSE:BMY) in 2014-18. McGrath is Biohaven’s...
...limitations of current single-cell RNA imaging tech (see “Arch Backs Vizgen’s RNA Imaging Platform”). Jeff Cranmer Merck KGaA Biohaven Pharmaceutical Holding Co. Ltd. Abeona...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...Clene Nanomedicine Inc., Ra Pharmaceuticals Inc. and Biohaven Pharmaceutical Holding Co. Ltd....
Items per page:
1 - 10 of 69
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...play BioShin Ltd. as COO in 2018 and is now CEO. BioShin, a Shanghai-based subsidiary of Biohaven Pharmaceutical Holding Co. Ltd....
BioCentury | Mar 30, 2021
Deals

March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest

...Lyfe Capital, Maven Investment Partners US, Lilly Asia Ventures and Eight Roads Ventures.Migraine milestone for Biohaven Enrollment...
...Phase II/III trial of oral migraine product zavegepant triggered a $100 million milestone payment to Biohaven Pharmaceutical Holding Co. Ltd....
...NYSE:BHVN) from Royalty Pharma plc (NASDAQ:RPRX).TARGETSPGE2 – Prostaglandin E2PPARα – Peroxisome proliferation activated receptorα BC Staff Zavegepant (BHV-3500) Qihan Biotechnology Inc. Biohaven Pharmaceutical Holding Co. Ltd. Royalty...
BioCentury | Mar 3, 2021
Finance

March 3 Venture Roundup: Bionaut debuts with $20M; plus Janux, Century, Caribou, Medilink, Oxular and more

...in a series A-2 round led by existing investor Hatteras Venture Partners and new investor Biohaven...
...also participating were CT Innovations, Elm Street Ventures and Osage University Partners. Artizan also granted Biohaven...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...commercialization rights to verdiperstat in ALS to Biohaven Pharmaceutical Holding Co. Ltd....
BioCentury | Jan 20, 2021
Product Development

Alzheimer’s marks fourth late-stage miss for Biohaven’s glutamate modulator

...By selina koch, executive editor Biohaven’s glutamate modulator troriluzole has missed its primary endpoint in a...
...neurological indication, this time Alzheimer’s disease. That won’t necessarily prevent the company from advancing the therapy.Biohaven Pharmaceutical Holding Co. Ltd....
...is a third-generation prodrug of riluzole, a generic with modest efficacy in amyotrophic lateral sclerosis. Biohaven...
BioCentury | Jan 8, 2021
Deals

Jan. 7 Quick Takes: Strong demand for Cullinan IPO; plus Bayer-CureVac COVID deal and venture rounds for Scorpion, Kira, Carisma and Abcuro and more

...other autoimmune diseases. The deal terms include $75 million in upfront Zai equity and $100 million in milestones and other payments.Biohaven...
...Kleo Pharmaceuticals Inc., acquiring two immune modulating platforms. The merger values Kleo at about $20 million. Biohaven...
...also entered a license agreement with Yale University for an extracellular target degrader platform. The company established Biohaven...
BioCentury | Dec 2, 2020
Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...Tuesday.Biohaven, Sosei Heptares in CGRP dealThe Sosei Heptares unit of Sosei Group Corp. (Tokyo:4565) granted Biohaven Pharmaceutical Holding Co. Ltd....
...up front plus research funding, and is eligible for $370 million in milestones, plus royalties. Biohaven...
...if that sale would cause or worsen a drug shortage. TARGETSCGRP – Calcitonin gene-related peptide BC Staff Biohaven Pharmaceutical Holding Co. Ltd. Sosei...
BioCentury | Oct 3, 2020
Product Development

Oral drugs and treatments for life-threatening diseases stand out among new product launches

...Brukinsa, the second-biggest increase was for migraine therapy Nurtec rimegepant, an oral disintegrating tablet from Biohaven Pharmaceutical Holding Co. Ltd....
...during the pandemic (see “Sizing Up Commercial Launches During Pandemic”). In its 2Q quarterly earnings report, Biohaven...
...ODT, rimegepant (BHV-3000, bms-927711) Ubrelvy, ubrogepant (MK-1602) Tepezza, teprotumumab (hzn-001, rv001, r1507, rg1507) BeiGene Ltd. Sage Therapeutics Inc. Novartis AG Amgen Inc. Biohaven Pharmaceutical Holding Co. Ltd. AbbVie...
BioCentury | Sep 29, 2020
Management Tracks

Garijo picked to succeed Oschmann at Merck KGaA; plus BioShin, Abeona, Rubius, Nimbus, Vizgen

...Mass., beginning April 1 at the latest; he is president of nutrition and biosciences at DuPont.Biohaven Pharmaceutical Holding Co. Ltd....
...was president and GM China of Bristol Myers Squibb Co. (NYSE:BMY) in 2014-18. McGrath is Biohaven’s...
...limitations of current single-cell RNA imaging tech (see “Arch Backs Vizgen’s RNA Imaging Platform”). Jeff Cranmer Merck KGaA Biohaven Pharmaceutical Holding Co. Ltd. Abeona...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...Clene Nanomedicine Inc., Ra Pharmaceuticals Inc. and Biohaven Pharmaceutical Holding Co. Ltd....
Items per page:
1 - 10 of 69